Fresenius lifts 2023 outlook for hospital drugs unit Kabi

<html xmlns=""><head><title>Fresenius lifts 2023 outlook for hospital drugs unit Kabi</title></head><body>

FRANKFURT, May 25 (Reuters) -German healthcare group Fresenius SE FREG.DE lifted its earnings target for generic hospital drugs unit Kabi, citing demand for blood plasma products and clinical nutrition and the planned launches of generic biotech drugs in the United States.

Kabi's 2023 sales, adjusted for currency swings, would likely grow by a "mid-single-digit" percentage, where it had previously predicted a "low-to mid-single-digit" gain, Fresenius said ahead of an investor event on Thursday.

It is now targeting an operating profit margin over sales of about 14%, up from about 13% seen previously.

Fresenius CEO Michael Sen, who took the helm last October, is cutting costs and has said the group would focus on Kabi and hospitals operator Helios, while dialysis business Fresenius Medical Care FMEG.DE and project development firm Vamed would be treated as financial investments.

Kabi and hospitals chain Helios accounted for 19% and 30% of first-quarter group sales, respectively.

Kabi is benefiting from "being there when there is more demand for plasma and when demand for clinical nutrition in hospitals is returning to pre-COVID levels," Sen told Reuters.

"To be there with innovative products is what's driving growth in the first quarter and what's making Kabi more confident," he added.

In addition, Kabi has invested heavily in its fledgling biosimilars business, a maker of lower-cost versions of complex biotech drugs that have lost patent protection, and has started launching products in the United States.

The company also specified that Kabi's operating profit margin would reach the upper end of its medium-term target range of 14%-17% by 2026.

Reporting by Ludwig Burger and Patricia Weiss
Editing by Madeline Chambers


免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。


本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。